Postmarketing Study of Empliciti in Korean Patients With Multiple Myeloma

Bristol-Myers Squibb

Overview

This study is a regulatory postmarketing surveillance study for Empliciti with a representative sample of the overall Korean multiple myeloma (MM) population.

Study Type

OBSERVATIONAL

Conditions

Multiple Myeloma

Interventions

Non-InterventionalOTHER

Non-Interventional

Eligibility

Sex: ALLMin age: 19 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Adult participants who have a confirmed diagnosis of Multiple Myeloma (MM) Exclusion Criteria: * Participants who use Empliciti for therapeutic indications which are not approved for Empliciti combination therapy in Korea * Patients in whom treatment with Empliciti (as clarified in the Korean label) is contraindicated Other protocol defined inclusion/exclusion criteria could apply

Locations (1)

Local Institution

Seoul, South Korea

Outcomes

Primary Outcomes

Incidence of AE's and SAE's

Time frame: 24 Months

Secondary Outcomes

Overall response of Empliciti treatment with lenalidomide and dexamethasone

Time frame: 24 Months

Incidence of infusion-related reactions associated with Empliciti treatment in combination with lenalidomide and dexamethasone

Time frame: 24 Months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.